FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
「This Fast Track designation is an encouraging step in our ongoing research and commitment to advancing care of those with systemic sclerosis with interstitial lung disease,」 said Christopher Cor......
